Imugene MD Talks JustStocks Through Bile Tract Cancer Expansion Study And New Strategic Partnership

Imugene Ltd (ASX: IMU) MD Leslie Chong caught up with JustStocks' Andrew Scott following the news enrolment has opened for the company's expansion study in bile tract cancer (cholangiocarcinoma) patients - part of its VAXINIA MAST clinical program. The expansion trial is expected to enrol 10 patients.
Chong also details a strategic manufacturing and process development partnership IMU has agreed with Kincell Bio. Kincell Bio is acquiring Imugene’s North Carolina manufacturing facility for up to USD$6 million in upfront and milestone-driven payments over three years. Chong says the deal extends Imugene's cash runway to 2026.
Leslie will be presenting at the JustStocks 'Stars In 2024 Series' in Melbourne on April 30th and Sydney May 1st. To register visit the Event Section at: www.juststocks.com.au